New Delhi: Amid the rising cases of COVID-19, there is a ray of hope in the battle against the deadly virus. A vaccine developed by the US-based biotech firm Moderna will enter the third and final stage of its clinical trial in July with 30,000 participants, reported France 24 today.
During this stage scientists will use a large healthy population and observe whether the vaccine is more effective in preventing COVID-19. They will also observe whether it can prevent infection with the coronavirus that causes the disease, the report stated.
The study framework was approved by the Food and Drug Administration (FDA) and is being conducted in collaboration with the US National Institutes for Health (NIH).
This apart, a vaccine is being developed by the University of Oxford with AstraZeneca, which has also launched a trial on 10,000 volunteers. The results of the trial are expected to be out by September.